Immix Biopharma, Inc. (IMMX)
14.31
+0.24
(+1.71%)
USD |
NASDAQ |
Aug 27, 16:00
14.31
0.00 (0.00%)
After-Hours: 20:00
Immix Biopharma Debt to Equity Ratio : 0.0044 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0044 |
| March 31, 2026 | 0.0123 |
| December 31, 2025 | 0.0114 |
| September 30, 2025 | 0.1339 |
| June 30, 2025 | 0.2241 |
| March 31, 2025 | 0.1104 |
| December 31, 2024 | 0.0811 |
| September 30, 2024 | 0.0621 |
| June 30, 2024 | 0.0457 |
| March 31, 2024 | 0.0392 |
| Date | Value |
|---|---|
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.0025 |
| December 31, 2021 | 0.0028 |
| September 30, 2021 | -0.6855 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Savara, Inc. | 0.2117 |
| SELLAS Life Sciences Group, Inc. | 0.0054 |
| Atossa Therapeutics, Inc. | 0.00 |
| Marker Therapeutics, Inc. | 0.00 |
| Krystal Biotech, Inc. | 0.0065 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 239.11M |
| Total Liabilities (Quarterly) | 10.19M |
| Shareholders Equity (Quarterly) | 228.92M |
| Current Ratio | 25.13 |
| Net Debt Paydown Yield | 0.00% |